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Abstract
OBJECTIVES—Cytokines and growth factors play a major role in the dysregulated immune
response in inflammatory bowel disease (IBD). We hypothesized that significant differences exist
between the serum cytokine and growth factor profiles of pediatric IBD patients with active disease
(AD) and those in remission, and that levels of some of these soluble mediators may be used to define
regulators in IBD and determine disease activity.
METHODS—Eighty-eight, consecutive patients with confirmed Crohn’s disease (CD) and
ulcerative colitis (UC) seen at the Duke Children’s Hospital were prospectively enrolled and a serum
sample was obtained. Data were recorded at the time of serum collection to calculate disease activity
indices. The relative expression of 78 cytokines, growth factors, and soluble receptors was
determined using proprietary antibody-based protein microarrays amplified by rolling circle
amplification. SPSS 8 (SPSS Inc., Chicago, IL) was used to compare protein profiles for CD and UC
patients in clinical remission (CR) versus AD.
RESULTS—Sixty-five CD patients and 23 UC patients were enrolled. Forty-one CD patients had
available samples and PCDAI results. Twenty-two patients were in remission PCDAI ≤ 12.5 (median
5), 19 patients had disease activity >15 (median 30). Univariate analysis revealed that PLGF, IL-7,
IL-12p40, and TGF-β1 cytokine levels were significantly elevated for patients in CR versus AD (p
< 0.01). Twelve UC serum samples had Seo/Truelove Witt AI for analysis. Five patients were in
remission by TW AI and Seo AI ≤ 110 and 7 patients had active mild-to-severe disease by TW and
Seo AI >110. Only one cytokine, IL12p40, showed significance between CR versus AD (p < 0.02).
CONCLUSIONS—Surprisingly, we found no differences in circulating levels of proinflammatory
cytokines but found that pediatric IBD patients in remission compared to those with AD had higher
levels of specific circulating cytokines, including the regulatory cytokines IL-12p40, and TGF-β1.
It may be that these cytokines directly regulate intestinal inflammation in IBD or reflect the activity
of T regulatory cells in negatively regulating the inflammatory response. Further studies will be
needed to validate our results to define the molecular pathways involved in the intestinal immune
response in man.
Reprint requests and correspondence:Howard A. Kader, M.D., Pediatric Gastroenterology Associates, The Children’s Hospital at
Sinai, 2411 W. Belvedere Ave, Ste 407, Baltimore, MD 21215..
NIH Public Access
Author Manuscript
Am J Gastroenterol. Author manuscript; available in PMC 2006 October 2.
Published in final edited form as:














Inflammatory bowel disease (IBD) is a chronic intestinal in-flammatory disease. The
underlying mechanisms for the development and continuation of this disease are poorly
understood. A multifactorial etiology for the pathogenesis of IBD has been suggested and for
some patients there is a genetic predisposition that leads to an unregulated intestinal immune
response to an environmental, dietary, or infectious agent. Cytokines generated by the cellular
and humoral immune responses play a major role in the regulation of the intestinal immune
system. Other intestinal molecular messengers involved in this process include growth factors,
prostaglandins, leukotrienes, and oxygen-free radicals (1). Cytokines are released by immune
cells and affect cellular activity, differentiation, and proliferation via autocrine, paracrine, and
endocrine actions (1,2). These proteins are able to induce inflammation but are also equally
important in suppressing inflammation and mediating repair and healing (1,2). It has been
suggested that cytokines may mediate disordered inflammatory events in IBD (3). There is
great interest in the role of cytokines released by activated immune cells in IBD. However, the
identities of cytokines and growth factors that regulate Crohn’s disease (CD) and ulcerative
colitis (UC) are still not clearly defined. Present understanding of the role cytokines play in
IBD extends primarily from mouse models and more recently is based on adult human studies.
There are only a few published pediatric studies addressing this issue (4,5).
We hypothesized that significant differences exist between the serum cytokine and growth
factor profiles of pediatric IBD patients with active disease (AD) and those in remission, and




All patients with documented IBD (CD or UC) diagnosed and verified by clinical, radiological,
endoscopic, and histological criteria followed in the Division of Pediatric Gastroenterology
and Nutrition in the Department of Pediatrics at the Duke Children’s Hospital were eligible
for this study. There were approximately 140 patients with IBD treated by the Division of
Pediatric Gastroenterology and Nutrition. Consecutive patients from November 1, 1999 to
October 31, 2001 were prospectively enrolled after obtaining informed consent/assent. A serum
sample was obtained from the patient and data were collected regarding the patient’s clinical
history, current physical examination and results of a complete blood count, erythrocyte
sedimentation rate, and albumin. Where available, the patient’s disease activity index, Pediatric
Crohn’s Disease Activity Index, or Seo ulcerative colitis Activity Index/TrueLove & Witt
Activity Index were determined at the time of serum collection (6–8). If not all the data results
were obtainable, the patients’ samples were excluded from the analysis. Reasons that excluded
some of the patients’ samples from the analysis included difficulties in obtaining the necessary
blood samples from pediatric patients, technical problems with collecting the CBC, ESR, and
albumin samples such as specimens clotting, if not all the pertinent data were recorded despite
the study design and forms used to try and capture all of this information or there was a sample
processing issue. The study was approved by the Duke University Institutional Review Board.
Samples
Following informed consent, one 3–5-cc blood Clotting Tube was collected at the time of other
routine laboratory studies performed for follow-up management of the patient’s IBD. The
serum was isolated from the Clotting Tube and frozen at −80°C until processed. Forty-one CD
patient samples (22 from patients in clinical remission (CR) and 19 from patients with active
CD) and 20 UC patient samples (5 in CR, 7 with AD, and 8 with unknown disease activity)
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were used. The levels of 78 different cytokines and growth factors were determined in the
serum samples using an antibody microarray and the serum cytokine profiles of IBD patients
were analyzed. The 78 cytokines and growth factors are as follows: Angiogenin (ANG),
Amphiregulin (AR), Brain-derived neurotrophic factor (BDNF), B-lymphocyte
chemoattractant (BLC [CXCL13]), Ciliary neurotrophic factor (CNTF), Epidermal growth
factor (EGF), Epithelial cell-derived neutrophil-activating peptide (ENA-78 [CXCL5]),
Eotaxin (Eot [CCL11]), Eotaxin-2 (Eot-2 [CCL24]), Fas (TNFRSF6), Fas (CD95), Fibroblast
growth factor-6 (FGF-6), Fibroblast growth factor-7 (FGF-7), Fibroblast growth factor-9
(FGF-9), fms-like tyrosine kinase-3 ligand (Flt-3 Lig), Granulocyte colony stimulating factor
(G-CSF), Glial cell-line-derived neurotrophic factor (GDNF), Granulocyte macrophage colony
stimulating factor (GM-CSF), Hemofiltrate CC chemokine 4 (HCC4 [CCL16]), I-309 (CCL1),
Inter-feron alpha (IFN-a), Interferon gamma (IFN-g), Interleukin 1 alpha (IL-1a [IL-1F1]),
Interleukin 1 beta (IL-1b [IL-1F2]), Interleukin 1 receptor antagonist (IL-1ra [IL-1F3]), Inter-
leukin 1 soluble receptor I (IL-1 sR1), Interleukin 2 (IL-2), Interleukin 2 soluble receptor alpha
(IL-2 sRa), Interleukin 3 (IL-3), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6),
Interleukin 6 soluble receptor (IL-6 sR), Interleukin 7 (IL-7), Interleukin 8 (IL-8 [CXCL8]),
Interleukin 10 (IL-10), Interleukin 11 (IL-11), Interleukin 12 p40 (IL-12 [p40]), Interleukin 12
p70 (IL-12 [p70]), Interleukin 13 (IL-13), In-terleukin 15 (IL-15), Interleukin 16 (IL-16),
Interleukin 17 (IL-17), Interleukin 18 (IL-18), Interferon gamma inducible protein 10 (IP-10
[CXCL10]), Leukemia inhibitory factor (LIF), Monocyte chemotactic protein 1 (MCP-1
[CCL2]), Monocyte chemotactic protein 2 (MCP-2 [CCL8]), Monocyte chemotactic protein
3 (MCP-3 [CCL7]), Macrophage colony stimulating factor (M-CSF), Macrophage-derived
chemokine (MDC [CCL22]), Macrophage migration inhibitory factor (MIF), Monokine
induced by interferon gamma (MIG [CXCL9]), Macrophage inflammatory protein 1 alpha
(MIP-1a [CCL3]), Macrophage inflammatory protein 1 beta (MIP-1b [CCL4]), Macrophage
inflamma-tory protein 1 delta (MIP-1d [CCL15]), Myeloid progenitor inhibitory factor 1
(MPIF-1 [CCL23]), Macrophage stimulating protein (MSP), Neutrophil Activating Peptide 2
(NAP-2 [CXCL7]), Neurotrophin 3 (NT-3), Neurotrophin 4 (NT-4), Oncostatin M (OSM),
Pulmonary and activation-regulated chemokine (PARC [CCL18]), Placental growth factor
(PLGF), Regulated upon activation, normal T expressed and presumably secreted (RANTES
[CCL5]), Stem cell factor (SCF), Stromal cell-derived factor 1 alpha (SDF-1a [CXCL12]),
Thymus- and activation-regulated chemokine (TARC [CCL17]), Transforming growth factor
beta 1 (TGF-b1), Transforming growth factor beta 3 (TGF-b3), Tumor necrosis factor receptor
I (TNF-RI), Tumor necrosis factor receptor II (TNF-RII), Tumor necrosis factor alpha (TNF-
a [TNFSF2]), Tumor necrosis factor beta (TNF-b [TNFSF1]), TNF-related apoptosis-inducing
ligand (TRAIL [TNFSF10]), Vascular endothelial growth factor (VEGF), Soluble CD23
(sCD23), Soluble glycopro-tein 130 (sgp130), Urokinase plasminogen activator receptor
(uPAR)
Microarray Manufacture
Antibody microarrays were printed using a Packard Biosciences (Downers Grove, IL) BCA-
II piezoelectric microarray dispenser on cyanosilane-coated glass slides divided by Teflon
boundaries into sixteen 0.5-cm diameter circular sub-arrays (Fig. 1). Monoclonal antibodies
for 78 cytokines (R&D Systems Inc., Minneapolis, MN; BD Biosciences Pharmingen, San
Diego, CA; Biosource International, Camarillo, CA; Endogen/Pierce Biotechnology, Inc.,
Rockford, IL) were dispensed in quadruplicate at a concentration of 0.5 mg/ml. Printed slides
were blocked as described (9) and stored at 4°C until use. Batches of slides were subjected to
a quality control consisting of incubation with a fluorescently labeled antimouse antibody,
followed by washing, scanning, and quantitation. Typically, the coefficient of variability (CV)
of antibody deposition in printing was <5%.
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Rolling Circle Amplification (RCA) Immunoassay
The assay was performed by a liquid-handling robot (Biomek 2000, Beckman Instruments,
Fullerton, CA), which was enclosed in an 80% humidified, HEPA-filtered, plexiglass chamber.
A 15-μl sample was applied to each subarray, and im-munoassays with RCA signal
amplification were performed as described (9). Slides were scanned (GenePix, Axon
Instruments Inc., Foster City, CA) at 10-μm resolution with laser setting of 100 and PMT setting
of 550. Mean pixel fluorescence was quantified using the fixed circle method in GenePix Pro
3.0 (Axon Instruments, Foster City, CA). The fluorescence intensity of quadruplicate
microarray features was averaged for each feature and sample, and the resulting cytokine values
were determined. For every slide, a set of blanks was run and the intensity values were used
to correct for background signal.
Data Quality Control
Samples were excluded from statistical analysis if fluorescent intensities were generally weak
(indicating sample degradation), if there were visible defects in the array (such as scratches),
or if there was high background signal. Analyses were performed using complete set of data
containing the levels of all 78 cytokines from 41 CD patient samples and 20 UC patient samples.
Untransformed fluorescent intensities were used as data values in all of the analyses.
Statistical Analysis
In order to determine the cytokines that contribute the most to discrimination between classes,
a stepwise method of linear discriminant analysis (LDA) from SPSS 8.0 (SPSS Inc., Chicago,
IL) for Windows was used with the following settings: Wilks’ lambda (Λ) method was used
to select cytokines that maximize the cluster separation and cytokine entrance into the model
was controlled by its F-value. A large F-value indicates that the level of the particular cytokine
is different between the two groups, and a small F-value (F < 1) indicates that there is no
difference. In this method, the null hypothesis is rejected for small values of Λ. Thus, the aim
was to minimize Λ. LDA was used to distinguish between two patient groups based on the
levels of multiple cytokines simultaneously. The goal of LDA was to build a classification
model and use it in cross-validation analysis. The absolute magnitude of the canonical function
values (CFVs) represents the contribution or the weight of that cytokine in the model. A large
CFV represents a large contribution of a given cytokine to classifications, and a small CFV
represents a small contribution. To construct a list of cytokine predictors, the F-values were
first calculated for each of the 78 cytokines. Cytokines with F-values <1 were rejected. Then
the value of Λ was determined for the cytokine with the largest F-value (the cytokine that
differs the most between the two groups). The cytokine with the next largest F-value was then
added to the list and Λ recalculated. If the addition of the second cytokine lowered the value
of Λ, it was kept in the list of cytokine predictors. The process of adding cytokines one at a
time was repeated until the reduction of Λ no longer occurred. Cross-validation, a method for
testing the robustness of a prediction model, was then carried out. To cross-validate a prediction
model, one sample was removed and set aside, the remaining samples were used to build a
prediction model based on the preselected cytokine predictors, and it was determined whether
the new model is able to predict the one sample not used in building the new model correctly.
This process was repeated for all samples one at a time, and a cumulative cross-validation rate
was calculated. The final list of cytokine predictors was determined by manually entering and
removing cytokines to maximize the cross-validation rate, using information obtained from
the univariate analyses and cross-validations. The final cytokine classifier was then defined as
the set of cytokine predictors that resulted in the highest cross-validation rate.
Univariate analysis of individual cytokine levels was performed by using the Kruskal-Wallis
test (analysis of variance by rank). The level of significance was set at a ≤ 0.01.
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Sixty-five CD patients and 23 UC patients were enrolled. Forty-one CD patients had available
samples and PCDAI results to analyze. The demographic data for these CD patients are shown
in Table 1. The mean CD patient age was 13.3 ± 3.7 yr (range 3–20 yr). Twenty-two CD patients
were in remission (PCDAI ≤ 12.5, median = 5), 11 patients had mild disease activity (PCDAI
15–30, median = 20), and 8 patients had moderate-to-severe activity (PCDAI ≥ 31, median =
43.75), as shown in Table 2 (for analysis, the “mild” and the “moderate to severe” activity
patients were grouped together in “active disease” group; n = 19, PCDAI median = 30). There
were no significant differences found between the groups with AD and remission groups in
age distribution at the time of study ( p = 0.4439), disease duration in months ( p = 0.1881), or
in medications (6-MP, AZA, MTX, p = 0.3522; infliximab, p = 0.5883; 5-ASA, p = 0.6847;
and prednisone, p = 0.752). Given the study design, there were not enough patients enrolled
to provide any statistically meaningful information regarding potential racial differences.
Tables 3 and 4 depict the demographics of the 35 excluded patients/analytes and show no
statistical difference in comparison to the characteristics of those patients included in the study
except for the difference in disease duration in the cohort of CD patients ( p = 0.02). The
majority of these were excluded because there was (i) no activity indices able to be derived so
those cannot be reported (n = 8 CD, 11 UC); (ii) despite enrollment a serum sample was never
collected from the consenting patient (n = 5 CD, 3 UC), or (iii) there was a sample processing
issue (n = 13 CD, 0 UC); so unfortunately, no speculation about how this difference may or
may not affect the study’s results can be made.
The Kruskal-Wallis test was initially used to compare CD patients in CR versus CD patients
with AD. Four cytokines, PLGF, IL-7, IL-12p40, and TGF-β1, showed significant differences
in their levels (Table 5). One of them, placenta growth factor (PLGF), was identified also by
linear discriminant analysis to be significantly different between the two groups, showing one
of the highest CFV (Table 6). Due to the importance of using replicates of the samples for
microarray studies in the design of this study and because the four significant replicates from
each sample were pooled by calculating the average intensity, Table 7 is provided here to
represent the display of variability among these replicates.
Using LDA, multiple cytokines were selected as described in Materials and Methods section
and used to build models for the CD active versus CD remission comparison using a different
number of cytokines (Fig. 2). A list of the cytokines used in building the cytokine classifiers
and their CFVs are shown in Table 6. A 10-cytokine classifier was built that correctly
categorized 92.7% of original grouped cases and 85.4% of cross-validated grouped cases. The
number of cytokines used in this classifier was within the range of maximum confidence level,
as shown in Figure 3. The red line depicted in Figure 3 shows the ability of LDA to predict
random samples as a function of number of predictors (cytokines) for 41 patients, a rough false
positive rate. Random data prediction rate was 0% for all models with less than 13 predictors.
Range of maximum confidence interval is from 1 to 13 to keep random data prediction rate at
0%. This 10-cytokine classifier was considerably more successful in correctly categorizing
patients in remission than those with active CD (Table 8). Using LDA, the following 10
biomarkers that correlate with CD activity were identified: BDNF, I-309, IL-17, MCP-1,
MPIF-1, PLGF, TARC, TRAIL, sCD23, UPAR.
Twelve UC serum samples with Truelove & Witt/Seo Activity Indices were available.
Demographic data of these patients are also listed in Table 1, mean age was 13.6 ± 4.0 yr (range
2–18 yr). Five patients were in CR by TW and Seo AI ≤110 and 7 patients had mild-to-severe
disease by TW and Seo AI >110 (Table 3). Only one cytokine, IL12p40, showed a significant
difference between CR and AD (Table 9).
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Many other proinflammatory cytokines known to be elevated in AD such as IL-2, IL-6, IL-10,
TNF-a, etc., were also evaluated; however, the differences were not found to be significant in
the statistical analysis comparing these various groups.
DISCUSSION
It has been postulated from adult IBD studies that TH1 cells mediate CD and TH2 cells are
more involved in UC (1,10–13). Regulatory T cells (so called Treg, or TH3 cells) are involved
in “oral tolerance” and downregulating the immune response (14–17).
Initial studies demonstrate that specific cytokine and chemokine levels in serum, and mRNA,
protein and protein receptor levels in the mucosa, may potentially prove to be unique markers
for the two subgroups of IBD. In vivo mRNA and/or protein levels of IL-2 and IFN-γ (TH1)
are increased in CD but not in UC (11,12,18–20). Similarly, increased tissue levels of IL-4
(TH2) and IL-10 mRNA have been found in UC and not in CD (21). Although serum levels of
soluble IL-2 receptor and IL-6, and tissue IL-2 and IFN-γ, were increased in active CD,
increased cytokine production has been documented even in “inactive” CD intestinal tissue
(1,11,12,22).
Current studies suggest that unique cytokine profiles occur during different clinical stages of
CD (10) and different medical therapy (23,24). For instance, increased IL-4 mRNA and
decreased IFN-γ mRNA were found in early postoperative ileal lesions in CD, whereas chronic
CD intestinal lesions were noted to have increased IL-2 and IFN-γ mRNA levels (10). Also,
thymus-expressed chemokine (TECK) and its receptor CCR9+ are not only selectively
expressed in small bowel but also their expression is significantly lower in inflamed small
bowel compared to uninvolved small bowel (25). Interestingly, CCR9+ lymphocytes are found
in higher abundance in patients with small bowel CD compared to patients with only colonic
CD (25).
The relevance and value of serum cytokine levels in relationship to the tissue expression of
these cytokines in relationship to disease have been discussed in prior reviews and through
other individual published manuscripts (1,2,11,12,20,22,26,27). Such studies have
demonstrated correlations between increased tissue IL-2 receptors and increased serum IL-2,
elevated TNF-alpha in tissue, and serum. Other studies have shown increased serum soluble
IL-2 receptor and serum IL-6 levels associated with increased tissue IL-2 and IFN gamma as
it relates to clinical disease activity (11,12,20,22). Indeed, Louis et al. demonstrated that high
serum levels of IL-6 in quiescent CD alone or with elevated serum levels of soluble TNF
receptors p55 and p75 or soluble IL-2 receptor was predictive of a relapse, while Kucharzik
et al. showed that serum IL-10 level was significantly associated with disease activity in both
CD and UC (28,29). However, not all cytokines expressed in the tissue of patients with IBD
are detectable in serum, for example, IL-1 and IL-8. Most of the cytokine research and
evaluation in IBD are being performed at the tissue level, where the disease is occurring and
typically by polymerase chain reaction amplification of mRNA transcripts, but such studies as
those above and ours demonstrate that serum analysis is also relevant. In fact, being able to
identify and create a model of those cytokines that are detectable in serum and how they may
correlate to disease activity would be of significant clinical importance in the management of
IBD. Noninvasive measures to perhaps more accurately assess disease activity at the
immunological/inflammatory level than that presently available by current rudimentary
evaluation with nonspecific factors such as ESR, HCT, and albumin would not only be easier
than their bowel resection counterparts or PCR studies on mucosal biopsies but would also
permit a noninvasive means to assess the disease activity state.
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Surprisingly, in the present study we did not find decreases in proinflammatory cytokines with
decreasing severity of the disease. Instead, we found that specific cytokines, PLGF, IL-7,
IL-12p40, and TGF-β1 in CD and IL-12p70 in UC, were increased during remission. The
potential activities of all these cytokines can be surmised, except for PLGF.
We will speculate on the potential activities only on the analytes found to be statistically
significant by univariate analysis using the Kruskal-Wallis test since analytes utilized by
modeling algorithms are often not significantly different when evaluated individually.
Regarding this issue, Tables 5 and 9 are the result of statistical analysis using the univariate
Kruskal-Wallis test, while Table 6 is the result of statistical analysis using multivariate analysis,
which evaluates the significance in the difference in means in “multidimensional space” formed
by the analytes in Table 6. Analytes from Table 6 do have differences in their fluorescence
intensities but these differences were not found to be statistically significant by the Kruskal-
Wallis test when compared individually and therefore were not included in Tables 5 and 9.
Both statistical approaches are applicable in this study and all of the analytes found to be
significant could be potentially relevant. Consequently, it is possible and very likely that the
analytes TRAIL, TARC, SCD23, I309, and MPIF1 as well as BDNF, IL-17, MCP-1, PLGF,
and UPAR, as shown in the prediction model (Fig. 2) are related to disease pathogenesis, but
their relationship is likely complex, and would be difficult to explain without extensive
experimentation that is beyond the scope of this manuscript.
TGF-β1 (transforming growth factor) is an “antiinflammatory” growth factor that counteracts
IL-1 and TNF-α modulates processes such as homing, cellular adhesion, chemotaxis, and
regulates T-cell homeostasis (30–33). It promotes maturation of intestinal epithelial cells,
collagen production, and healing in wounds and ulcers. It has inhibitory properties on
cytotoxicity and its proliferative responses interfere with the IL-12 pathway by inhibiting IFN-
γproduction, the early signal transduction events of the IL-12/IL-12 receptor complex, and the
phosphorylation of the STAT4 transcription factor (34). TGF-β1 expression in both CD and
UC has been shown to depend on the presence and location of the inflammation rather than on
the type of IBD (35,36). Most importantly, TGF-β1 is thought to convert T cells into regulatory
(Treg) cells and to perpetuate the antiinflammatory effects of these cells (37). Thus, increased
TGF-β1 during remission of CD is plausible.
IL-7 has a crucial role in the organization of mucosal lymphoid tissue, acting on both B and T
cells, and in the regulation of a normal T-cell immune response (38–43). It also promotes
homeostatic proliferation of memory CD8 cells (44) by inhibiting pre-T-cell differentiation
specifically at the point of conversion of T-cell receptor αβ development, thereby, selectively
promoting memory CD8 cell differentiation (45). Early studies suggested that IL-7 may act
synergistically with IL-12 to stimulate TNF-α and a TH1 response but recent studies suggest
it actually promotes a TH2 response with increased IL-10 and MCP-1, while decreasing TH1
cytokines, for example, IL-2, IFN-γ, and RANTES (46–48). Furthermore, IL-7 inhibits Treg
suppression of TH1 cells while having no effect on the suppression of TH2 cells (37). The
elevation of IL-7 in CD patients in remission is thus plausible.
IL-12 is a disulfite-linked heterodimer (IL-12p70) composed of a heavy chain, p40, and a light
chain, p35, produced by phagocytic and antigen presenting cells. IL-12p40 is a cytokine with
immunoregulatory, antitumor, and antimetastatic properties favoring a TH1 pattern and
inhibiting a TH2 response (49–55). In the present study there was a significant elevation of
IL-12p40, but not IL-12p70 in CD and UC patients in remission. Levels of p40 and the p70
heterodimer are not necessarily linked. The amount of the p40 subunit may in some cases be
present far in excess of the heterodimer. IL-12p70 heterodimer is a key player in the TH1
inflammatory pathway but the p40 subunit alone has very different activities as compared to
the IL-12p70 heterodimer. As a result, the IL-12p70 and IL-12p40 represent two different
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analytes and two distinct responses. A recent report studying sepsis patients suggests that an
over expression of IL-12p40 regulatory subunit may be part of a pathway that controls
inflammation (56). In support of this idea, it is known that IL-12p40 can form homodimers
that antagonize the activity of the IL-12p70 heterodimer (57). The fact that the p40 subunit is
known to antagonize the activity of the IL-12 heterodimer provides a potential mechanism for
inhibition of the chronic IL-12-dependent inflammatory response and improvement of
symptoms. This is consistent with the hypothesis that IL-12p40 participates in the pathway
that suppresses disease activity.
Placenta-derived growth factor (PLGF) and vascular endothelial growth factor (VEGF)
represent two closely related angiogenic growth factors active as homodimers or heterodimers
(58). PLGF strongly potentiates both the proliferative and the permeabilization effects exerted
by VEGF on the vascular endothelium (58). The serum levels of VEGF have been found to be
increased and to correlate with disease activity in patients with IBD, indicating a role for this
cytokine in modulating inflammation in these chronic inflammatory diseases. The mechanism
of action may be through increasing the vascular permeability and/or wound healing via its
proangiogenic effects (4). Interestingly, monocytes express the VEGF receptor Flt-1, which
specifically binds the VEGF homolog PLGF also. Both VEGF and PLGF stimulate tissue factor
production and chemotaxis in monocytes at equivalent doses. It has been suggested that Flt-1
is a functional receptor for VEGF and PLGF in monocytes and endothelial cells, and a mediator
of monocyte recruitment and procoagulant activity (59). At this time, it is unclear why PLGF
may be increased during the remissive phase of CD. It is possible that increased PLGF may
promote wound healing by its proangiogenic effects.
Speculation as to the importance of these serum cytokines and growth factors in CD and UC
remission states may relate to the antiinflammatory and wound-healing properties of these
immune regulatory proteins. Increased PLGF may promote wound healing by its proangiogenic
effects. Increased IL-7 is important in regulating the normal immune response in intestinal
mucosa and decreasing the TH1 activity. TGF-β1 may also dampen T-cell immune reactivity
and the associated inflammatory response by downregulating IL-1 and TNF-α and by
interfering with the IL-12/TH1 response. TGF-β1 can also promote wound/ulcer healing and
the maturation of replacement intestinal epithelial cells, and may assist in the body’s
“tolerance” to a repetitively encountered antigen associated with the patient’s IBD. In fact,
Neurath et al. have demonstrated in 2,4,6-trinitrobenzene sulfonic acid (TNBS) models of
TH1 chronic colitis pretreated with haptenated colonic proteins as oral tolerance, that the
effective suppression of this inducible colitis is directly associated with the production of TGF-
β from mucosal T cells (60). Increased serum IL-12p40 in this setting may appear to be
paradoxical but the antagonistic effects of IL-12p40 homodimer toward the IL-12p70
heterodimer could explain this finding and may represent a potential mechanism for the
changes in disease activity. IL-12p40 may also reflect the primary TH1 response exhibited by
patients with CD and may assist in cell trafficking. Finally, given the balance of inflammatory
and antiinflammatory mediators at work in IBD, increased serum levels of TGF-β1 may reflect
the body’s immune response to maintain CR.
Our study demonstrated a large standard deviation regarding the results of the analytes.
Nevertheless, the p-values in this context are still relevant and very much valid as it incorporates
the standard deviation of the groups. The standard deviations identified should be considered
in context of the difference in means between the groups. Effect size is the difference in-group
means divided by a standard deviation. For example, effect size of PLGF (Table 5) would be
0.92. This would then translate into the fact that 82% of cases in the CD active group will be
below average compared to the CD remission group. Unfortunately, we cannot make large
claims as to the relevance of our findings to clinical diagnostics. As this study is an initial one,
our findings will need to be validated.
Kader et al. Page 8













We have used univariate and linear determinant analyses to define potential biomarkers and
algorithms to predict disease activity in IBD. While these algorithms are not yet validated, they
do provide a basis from which to build possible classifiers for disease activity in IBD.
WHAT IS ACCEPTED AND WHAT THIS RESEARCH ADDS
• Additional Pediatric cytokine/growth factor data in IBD for which there is minimal
to scant published information.
• Correlation of serum cytokine/growth factors with disease activity
• Correlation of serum cytokine/growth factors with IBD disease type
• Ability to use a noninvasive means to assess disease characteristics and activity with
limited blood volume compared to standard large volume samples typically required
for ELISA making such use practical in the pediatric population
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Schematic representation of a sample protein microarray slide with 16 subarrays. Subarrays
refer to the 16 wells (A–L and 4 control subarrays), or circular analysis sites, on the slide. Array
refers to the antibody content printed in a well. Spots with capture antibodies are deposited in
each subarray. The number of spots is for illustration purpose only.
Kader et al. Page 13














Group separation based on canonical function values obtained by linear discriminant analysis
(LDA) for comparing CD patients in clinical remission versus CD patients with active disease.
Each square represents one individual. Left panel, prediction model based on four cytokines
(TRAIL,TARC,PLGF,SCD23). Right panel, prediction model based on 10 cytokines (BDNF,
I-309, IL-17, MCP-1, MPIF-1, PLGF, TARC, TRAIL, SCD23, UPAR). Abbreviations
identified in Materials and Methods section.
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PPV, sensitivity, cross-validation rate, and prediction rate (saturation capacity) of LDA-based
models of comparing CD patients in clinical remission versus CD patients with active disease.
X-axis represents number of cytokines used as classifiers; Y-axis represents the percentage
value of the corresponding parameter, PPV, cross-validation rate, sensitivity, or saturation
capacity. The number of cytokine predictors used in building a prediction model influences
the model’s correct prediction confidence level.
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Table 1
Demographic Data of Patients Used
Crohn’s Disease (n = 41) Ulcerative Colitis (n = 12)
Age (yr) 13.3 ± 3.7 (range 3–20) 13.6 ± 4 (range 2–18)
Male/female 26/15 6/6
Race 32 White, 9 Black 9 White, 2 Black, 1 Hispanic






 Small bowel 9 N/A
 TI/Colon 25 N/A
 Colon 7 10 pancolonic/2 left sided
 Perianal 5
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Table 2
Disease Activity Index of Patients Used
No. of Patients Median AI Score
PCDAI
 Remission (=12.5) 22 5
 Mild (15 – 30) 11 20





 Remission (=110) 5 94.6
 Active 7 187.1
 Mild (111–<150) n = 2
 Moderate(150–<220) n = 3
 Severe (>220) n = 2













Kader et al. Page 18
Table 3
Demographic Data of Patients Excluded
Crohn’s Disease (n = 24) Ulcerative Colitis (n = 11)
Age (yr) 13.6 ± 4.4 (range 5–21) 15.5 ± 3.5 (range 10–21)
Male/female 13/11 6/6
Race 20 White, 4 Black 8 White, 2 Black, 1 Hispanic






 Small bowel 2 N/A
 TI/Colon 12 N/A
 Colon 10 10 pancolonic/1 left sided
 Perianal 2













Kader et al. Page 19
Table 4
Disease Activity Index of Patients Excluded
No. of Patients (n = 24 CD), (n = 11 UC) Median AI Score
PCDAI
 Remission (≤12.5) 12 5
 Mild (15 – 30) 2 17.5











There were no activity indices able to be derived due to lack of data for these UC patients.
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Table 6
Cytokine Predictors and Their Canonical Function Values for Different Classifiers
Comparison Classifier: Cytokine Predictor Canonical Function Value (CFV)
CD patients (clinical remission)


















TRAIL = TNF-related apoptosis-inducing ligand; TARC = Thymus- and activation-regulated chemokine; PLGF = Placental growth factor; SCD23 =
Soluble CD23; BDNF = Brain-derived neurotrophic factor, I-309; IL-17 = Interleukin-17; MCP-1 = Monocyte chemotactic protein 1; MPIF-1 = Myeloid
progenitor inhibitory factor 1; UPAR = Urokinase plasminogen activator receptor.
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Table 7
Coefficient of Variability Among a Sample of the Replicate Analytes
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